Matthew Harrison
Stock Analyst at Morgan Stanley
(3.52)
# 804
Out of 5,182 analysts
685
Total ratings
50.35%
Success rate
4.36%
Average return
Main Sectors:
Stocks Rated by Matthew Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $120 → $119 | $54.06 | +120.13% | 24 | May 5, 2026 | |
| BIIB Biogen | Maintains: Equal-Weight | $200 → $206 | $193.45 | +6.49% | 58 | Apr 30, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $769 → $796 | $714.89 | +11.35% | 60 | Apr 10, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $171 → $175 | $131.33 | +33.25% | 45 | Apr 10, 2026 | |
| INSM Insmed | Upgrades: Overweight | $166 → $212 | $101.35 | +109.18% | 21 | Mar 30, 2026 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $40 → $42 | $19.62 | +114.07% | 14 | Mar 26, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $50 → $49 | $28.12 | +74.25% | 15 | Mar 11, 2026 | |
| R Ryder System | Maintains: Positive | $235 → $250 | $239.14 | +4.54% | 2 | Feb 13, 2026 | |
| MRNA Moderna | Maintains: Equal-Weight | $30 → $28 | $54.35 | -48.48% | 27 | Dec 12, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $1,070 → $1,110 | $782.17 | +41.91% | 27 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $41 | $30.09 | +36.26% | 16 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $4 | $4.41 | -9.30% | 5 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $460 → $439 | $429.82 | +2.14% | 41 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $20 | $19.96 | +0.23% | 38 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6.2 → $6 | $5.43 | +10.50% | 10 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $5 | $1.00 | +400.00% | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $56 | $36.89 | +51.80% | 2 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 → $55 | $25.40 | +116.54% | 2 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $3 | $2.10 | +42.86% | 10 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $39.60 | -72.22% | 9 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 | $3.11 | +125.08% | 18 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $32 | $26.43 | +21.07% | 27 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $21 → $19 | $3.21 | +491.90% | 3 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $2 → $1 | $1.50 | -33.33% | 3 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $10 | $22.89 | -56.31% | 9 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 → $8 | $7.01 | +14.12% | 9 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $3.51 | +270.37% | 3 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $80 | $19.33 | +313.86% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $60 | $4.78 | +1,155.23% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $203 → $216 | $94.13 | +129.48% | 8 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.50 | +42.86% | 13 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $5 | $3.69 | +35.50% | 6 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $182 | $201.55 | -9.70% | 8 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $9 | $41.01 | -78.05% | 13 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $279 → $282 | $331.70 | -14.98% | 38 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $220 → $210 | $295.05 | -28.83% | 7 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $55 → $52 | $25.68 | +102.49% | 5 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $175 → $173 | $221.32 | -21.83% | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $156 → $120 | $26.12 | +359.42% | 17 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $145 → $148 | $9.86 | +1,401.01% | 19 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $82 | $111.38 | -26.38% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $71 → $66 | $56.16 | +17.52% | 4 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $39 | $6.81 | +472.69% | 4 | Aug 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $46 | $50.79 | -9.43% | 1 | Aug 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $33 → $35 | $13.35 | +162.17% | 1 | Aug 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $207 → $275 | $948.45 | -71.01% | 2 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $2.85 | +566.67% | 1 | Jun 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $62 | $10.55 | +487.68% | 12 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $16.12 | +7.01% | 3 | Feb 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $89 → $83 | $98.56 | -15.79% | 1 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $10 | $76.91 | -87.00% | 4 | Sep 10, 2018 |
BioMarin Pharmaceutical
May 5, 2026
Maintains: Overweight
Price Target: $120 → $119
Current: $54.06
Upside: +120.13%
Biogen
Apr 30, 2026
Maintains: Equal-Weight
Price Target: $200 → $206
Current: $193.45
Upside: +6.49%
Regeneron Pharmaceuticals
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $769 → $796
Current: $714.89
Upside: +11.35%
Gilead Sciences
Apr 10, 2026
Maintains: Overweight
Price Target: $171 → $175
Current: $131.33
Upside: +33.25%
Insmed
Mar 30, 2026
Upgrades: Overweight
Price Target: $166 → $212
Current: $101.35
Upside: +109.18%
Denali Therapeutics
Mar 26, 2026
Maintains: Overweight
Price Target: $40 → $42
Current: $19.62
Upside: +114.07%
Legend Biotech
Mar 11, 2026
Maintains: Overweight
Price Target: $50 → $49
Current: $28.12
Upside: +74.25%
Ryder System
Feb 13, 2026
Maintains: Positive
Price Target: $235 → $250
Current: $239.14
Upside: +4.54%
Moderna
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $30 → $28
Current: $54.35
Upside: -48.48%
argenx SE
Dec 4, 2025
Maintains: Overweight
Price Target: $1,070 → $1,110
Current: $782.17
Upside: +41.91%
Dec 4, 2025
Maintains: Overweight
Price Target: $37 → $41
Current: $30.09
Upside: +36.26%
Nov 12, 2025
Maintains: Equal-Weight
Price Target: $8 → $4
Current: $4.41
Upside: -9.30%
Aug 5, 2025
Maintains: Equal-Weight
Price Target: $460 → $439
Current: $429.82
Upside: +2.14%
Jul 29, 2025
Maintains: Equal-Weight
Price Target: $15 → $20
Current: $19.96
Upside: +0.23%
Apr 11, 2025
Maintains: Equal-Weight
Price Target: $6.2 → $6
Current: $5.43
Upside: +10.50%
Mar 12, 2025
Maintains: Overweight
Price Target: $15 → $5
Current: $1.00
Upside: +400.00%
Feb 18, 2025
Upgrades: Buy
Price Target: $56
Current: $36.89
Upside: +51.80%
Jan 31, 2025
Maintains: Buy
Price Target: $57 → $55
Current: $25.40
Upside: +116.54%
Nov 26, 2024
Downgrades: Underweight
Price Target: $10 → $3
Current: $2.10
Upside: +42.86%
Jun 21, 2024
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $39.60
Upside: -72.22%
May 9, 2024
Upgrades: Equal-Weight
Price Target: $7
Current: $3.11
Upside: +125.08%
Mar 26, 2024
Maintains: Underweight
Price Target: $32
Current: $26.43
Upside: +21.07%
Aug 14, 2023
Maintains: Equal-Weight
Price Target: $21 → $19
Current: $3.21
Upside: +491.90%
Mar 27, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $1.50
Upside: -33.33%
Mar 3, 2023
Maintains: Underweight
Price Target: $13 → $10
Current: $22.89
Upside: -56.31%
Feb 28, 2023
Downgrades: Equal-Weight
Price Target: $27 → $8
Current: $7.01
Upside: +14.12%
Jan 24, 2023
Maintains: Overweight
Price Target: $15 → $13
Current: $3.51
Upside: +270.37%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $140 → $80
Current: $19.33
Upside: +313.86%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $100 → $60
Current: $4.78
Upside: +1,155.23%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $203 → $216
Current: $94.13
Upside: +129.48%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.50
Upside: +42.86%
Jan 24, 2023
Maintains: Overweight
Price Target: $7 → $5
Current: $3.69
Upside: +35.50%
Dec 6, 2022
Maintains: Overweight
Price Target: $178 → $182
Current: $201.55
Upside: -9.70%
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $12 → $9
Current: $41.01
Upside: -78.05%
Nov 4, 2022
Maintains: Overweight
Price Target: $279 → $282
Current: $331.70
Upside: -14.98%
Oct 28, 2022
Maintains: Equal-Weight
Price Target: $220 → $210
Current: $295.05
Upside: -28.83%
May 4, 2022
Maintains: Equal-Weight
Price Target: $55 → $52
Current: $25.68
Upside: +102.49%
Apr 6, 2022
Maintains: Equal-Weight
Price Target: $175 → $173
Current: $221.32
Upside: -21.83%
Feb 1, 2022
Maintains: Overweight
Price Target: $156 → $120
Current: $26.12
Upside: +359.42%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $145 → $148
Current: $9.86
Upside: +1,401.01%
Nov 29, 2021
Maintains: Equal-Weight
Price Target: $88 → $82
Current: $111.38
Upside: -26.38%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $71 → $66
Current: $56.16
Upside: +17.52%
Aug 18, 2021
Maintains: Overweight
Price Target: $43 → $39
Current: $6.81
Upside: +472.69%
Aug 16, 2021
Maintains: Equal-Weight
Price Target: $51 → $46
Current: $50.79
Upside: -9.43%
Aug 16, 2021
Maintains: Equal-Weight
Price Target: $33 → $35
Current: $13.35
Upside: +162.17%
Aug 5, 2021
Maintains: Overweight
Price Target: $207 → $275
Current: $948.45
Upside: -71.01%
Jun 24, 2021
Initiates: Buy
Price Target: $19
Current: $2.85
Upside: +566.67%
Mar 8, 2021
Maintains: Overweight
Price Target: $67 → $62
Current: $10.55
Upside: +487.68%
Feb 24, 2021
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $16.12
Upside: +7.01%
Jan 6, 2020
Maintains: Equal-Weight
Price Target: $89 → $83
Current: $98.56
Upside: -15.79%
Sep 10, 2018
Assumes: Equal-Weight
Price Target: $10
Current: $76.91
Upside: -87.00%